EXPRESS MAIL NO. EV449556656US

3-29-59 Emore

TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

Application Number	09/685,830
Filing Date	October 9, 2000
First Named Inventor	Alexander Gaiger
Art Unit	1644
Examiner Name	Ronald B. Schwadron
Attorney Docket No.	210121.465C3

	<u>E</u> r	NCLOSURES (check all that app	<i>ly</i>)		
Fee Transmitta Fee Attach Amendment/Ro After Final Affidavits/o Extension of To Express Aband Request Third Supplem Information Dis Statement; For 3 Cited Refere Certified Copy Document(s) Response to M under 37 C.F.F. Response to M Parts/Incomple	al Form ned esponse declaration(s) ime Request donment ental sclosure rm PTO-1449 nces of Priority lissing Parts R. 1.52 or 1.53	Drawing(s) Request for Corrected Filing Receipt Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation, Change of Correspondence Address Declaration Statement under 37 CFR 3.73(b) Terminal Disclaimer Request for Refund	CD(s), Number of CD(s) After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Return Receipt Postcard Additional Enclosure(s) (please identify below):		
Remarks					
	SIGNATUR	RE OF APPLICANT, ATTORNEY,	OR AGENT		
Individual Name	Julie A. Urvat Reg. No. 50,4	ter, Ph.D., Patent Agent 461	Customer Number 00500		
Signature	Chile	1 Uwah			
Date	March 26, 20	04			
CERTIFICATE OF TRANSMISSION/MAILING					
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.					
Typed or printed n	ame	, ·			
Signature		,	Date:		
	s required by 37 CFR 1.5	5. The information is required to obtain or retain a benefit			

process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

TOTAL AMOUNT OF PAYMENT

37 CFR 1.27.

180.00

OIPE			
	2718	FEE TRANSM	
MAR 2 6	W 400	for FY 20	104
		Patent fees are subject to an	nual revision.
COMME	Appli	cant claims small entity status.	See 37 CFR 1.2

Complete if Known			
Application Number	09/685,830		
Filing Date	October 9, 2000		
First Named Inventor	Alexander Gaiger		
Examiner Name	Ronald B. Schwadron		
Art Unit	1644		
Attorney Docket No.	210121.465C3		

		ME	THOD O	F PAYMENT_	
	ment Encl	Credit c	ard 📗	Money Order	Other
A	eposit ccount lumber	19-10	90		
A	eposit ccount lame	Seed PLLC	Intellec	tual Property La	w Group
The Dire	Charge fee Charge an Charge fee	e(s) indicat y additiona	ed below at fee(s) d ed below	k all that apply) Credit a Uning the pendency except for the fili	
to the ab	ove-identifi	ed deposit	account.		
		F	EE CAL	CULATION	
1. BAS	SIC FILING	FEE	-		
Large E Fee Code		mall Entit	Y ee(\$)	Fee Description	Fee Paid
1001	770	2001	385	Utility filing fee	Paid
1001	340	2001	170	Design filing fee	-
1002	530	2002	265	Plant filing fee	
1003	770	2004	385	Reissue filing fee	-
1005	160	2005	80	Provisional filing	
		2000	00	fee	
				SUBTOTAL (1)	(\$)
0 EVT	5 4 61 4 II	FFF0 F6	D UTU I		
2. <u>EXT</u>	RA CLAIM	FEESFO	RUTILI	TY AND REISSUE	
Total Cla			-" = [-" = [Extra froi claims belo	m Fee
Multiple Depende	nt.				=
<u>Large</u>	Entity	Small E	ntity		
Fee	Fee	Fee	Fee	Fee Description	ı
Code 1202	(\$)	Code	(\$)	•	
1202	18 86	2202 2201	9 43	Claims in excess	ms in excess of 3
1201	290	2201	145	•	ent claim, if not paid
1204	86	2204	43	** Reissue indep original patent	endent claims over
1205	18	2205	9	** Reissue claim and over origi	s in excess of 20 nal patent
**or num	aber previou	sly naid if o		TOTAL (2) (\$	
31 11011	providu	, poid, ii <u>c</u>	,	эсс авоу	~

FEE CALCULATION (continued)					
3. ADDITIONAL FEES					
Large E		Sm	all		
Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet.	
1053	130	1053	130	Non-English specification	
1812	2520	1812	2520	For filing a request for ex parte reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1840*	1805	1840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	420	2252	210	Extension for reply within second month	
1253	950	2253	475	Extension for reply within third month	
1254	1480	2254	740	Extension for reply within fourth month	
1255	2010	2255	1005	Extension for reply within fifth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing a brief in support of an appeal	
1403	290	2403	145	Request for oral hearing	
1451	1510	1451	1510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1330	2453	665	Petition to revive – unintentional	
1501	1330	2501	665	Utility issue fee (or reissue)	
1502	480	2502	240	Design issue fee	
1503	640	2503	320	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	770	2809	385	Filing a submission after final rejection (37 CFR § 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37 CFR § 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	
Other fee (specify)					
*Reduce	d by Bas	sic Filing	Fee Pa	sid SUBTOTAL (3) (\$) 180	.00

Name (Print/Type) Julie A. Urvater, Ph.D., Patent Agent Registration No. Attorney/Agent) 50,461 Signature Date March 26, 2004 00500		SUBMITTED BY		· .	Customer Number
Signature Date March 26, 2004 00500		Julie A. Urvater, Ph.D., Patent Agent		1 50 451	Customer Number
	Signature	Culie Droat	Date	March 26, 2004	00500

This collection of information is required by 3' CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application of confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



EXPRESS MAIL NO. EV449556656US -

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Alexander Gaiger et al.

Application No.

09/685,830

Filed

October 9, 2000

For

COMPOSITIONS AND METHODS FOR WT1 SPECIFIC

IMMUNOTHERAPY

Examiner

Ronald B. Schwadron

Art Unit

1644

Docket No.

210121.465C3

Date

March 26, 2004

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached Form PTO-1449 (copies of the cited references are enclosed). As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

03/29/2004 KBETEMA1 00000119 09685830

01 FC:1806

180.00 OP

Please acknowledge receipt of this Third Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

A fee of \$180 is submitted in accordance with 37 C.F.R. § 1.97(c). The Director is authorized to charge any other fees which may be required, or credit any overpayment to Deposit Account No. 19-1090.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC

Julie A. Urvater, Ph.D., Patent Agent

Registration No. 50,461

JAU:ljt

MAR 2 6 2004

Enclosures:

Postcard Check for \$180 Transmittal Form Fee Transmittal Form (+1) Form PTO-1449 Cited References (3)

701 Fifth Avenue, Suite 6300 Seattle, Washington 98104-7092

Phone: (206) 622-4900 Fax: (206) 682-6031

\469051

EXPRESS MAIL NO. EV449556656US Sheet <u>1</u> of <u>1</u> ATTY. DOCKET NO. APPLICATION NO. U.S. DEPARTMENT OF COMMERCE (REV.7-80) . PATENT AND TRADEMARK OFFICE 210121.465C3 09/685,830 HIRD SUPPLEMENTAL APPLICANTS Alexander Gaiger et al. TION DISCLOSURE STATEMENT (Use several sheets if necessary) FILING DATE **GROUP ART UNIT** October 9, 2000 1644 **U.S. PATENT DOCUMENTS** *EXAMINER FILING DATE DOCUMENT NUMBER DATE NAME CLASS SUBCLASS INITIAL IF APPROPRIATE 6,096,313 08/01/00 Jäger et al. 424 184.1 ΑB AC AD ΑE AF AG ΑH Αl ΑJ **FOREIGN PATENT DOCUMENTS** DOCUMENT TRANSLATION DATE COUNTRY NUMBER ΑK ΑL AM AN ΑO OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AP	Boon, T., "Tumor Antigens Recognized By Cytolytic T Lymphocytes: Present Perspectives for Specific Immunotherapy," <i>Int. J. Cancer</i> 54: 177-180, 1993.
AQ	Oka, Y. et al., "Wilms Tumor Gene Peptide–Based Immunotherapy for Patients with Overt Leukemia from Myelodysplastic Syndrome (MDS) or MDS with Myelofibrosis," <i>International Journal of Hematology</i> 78: 56-61, 2003.
AR	

EXAMINER DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).